Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Natl Cancer Inst ; 93(17): 1325-30, 2001 Sep 05.
Article in English | MEDLINE | ID: mdl-11535707

ABSTRACT

BACKGROUND: Human papillomavirus 16 (HPV16) has a number of variants, each with a different geographic distribution and some that are associated more often with invasive neoplasias. We investigated whether the high incidence of cervical cancer in Mexico (50 cases per 100 000 women) may be associated with a high prevalence of oncogenic HPV16 variants. METHODS: Cervical samples were collected from 181 case patients with cervical cancer and from 181 age-matched control subjects, all from Mexico City. HPV16 was detected with an E6/E7 gene-specific polymerase chain reaction, and variant HPV classes and subclasses were identified by sequencing regions of the E6 and L1/MY genes. Clinical data and data on tumor characteristics were also collected. All statistical tests were two-sided. RESULTS: HPV16 was detected in cervical scrapes from 50.8% (92 of 181) of case patients and from 11% (20 of 181) of control subjects. All HPV16-positive samples, except one, contained European (E) or Asian-American (AA) variants. AA and E variants were found statistically significantly more often in case patients (AA = 23.2% [42 of 181]; E = 27.1% [49 of 181]) than in control subjects (AA = 1.1% [two of 181]; E = 10% [18 of 181]) (P<.001 for case versus control subjects for either E or AA variants, chi2 test). However, the frequency of AA variants was 21 times higher in cancer patients than in control subjects, whereas that ratio for E variants was only 2.7 (P =.006, chi2 test). The odds ratio (OR) for cervical cancer associated with AA variants (OR = 27.0; 95% confidence interval [CI] = 6.4 to 113.7) was higher than that associated with E variants (OR = 3.4; 95% CI = 1.9 to 6.0). AA-positive case patients (46.2 +/- 12.5 years [mean +/- standard deviation]) were 7.7 years younger than E-positive case patients (53.9 +/- 12.2 years) (P =.004, Student's t test). AA variants were associated with squamous cell carcinomas and adenocarcinomas, but E variants were associated with only squamous cell carcinomas (P =.014, Fisher's exact test). CONCLUSIONS: The high frequency of HPV16 AA variants, which appear to be more oncogenic than E variants, might contribute to the high incidence of cervical cancer in Mexico.


Subject(s)
Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/complications , Tumor Virus Infections/complications , Uterine Cervical Neoplasms/epidemiology , Uterine Cervical Neoplasms/virology , Adenocarcinoma/epidemiology , Adenocarcinoma/virology , Adult , Aged , Asia/ethnology , Asian People/genetics , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/virology , Case-Control Studies , DNA, Viral/genetics , Europe/ethnology , Female , Genetic Variation , Humans , Incidence , Mexico/epidemiology , Middle Aged , Odds Ratio , Papillomavirus Infections/virology , Polymerase Chain Reaction , Prevalence , Sequence Analysis, DNA , Tumor Virus Infections/virology , White People/genetics
4.
Rev Infect Dis ; 9 Suppl 1: S128-30, 1987.
Article in English | MEDLINE | ID: mdl-3027837

ABSTRACT

Forty-two patients with pityriasis versicolor were treated with itraconazole. Patients were allocated randomly to one of two groups; the first group (22 patients) received 200 mg of itraconazole per day for five days, and the second group (20 patients) received 100 mg per day for the same period. The study lasted 30 days. Each patient's clinical history was recorded before treatment. Wood's light examination was also done at this time and was repeated weekly. Direct microscopic examination of lesions was undertaken at the beginning, middle, and end of the trial. Specimens for cultures could be obtained from only 24 patients. The cure rate was 95% in the first group and 75% in the second. The difference between these rates was not significant, but the groups were small and the difference in dosage may ultimately be meaningful in terms of rates of cure. Itraconazole appears to be effective in a high percentage of cases of pityriasis versicolor.


Subject(s)
Antifungal Agents/therapeutic use , Ketoconazole/analogs & derivatives , Tinea Versicolor/drug therapy , Adult , Antifungal Agents/administration & dosage , Clinical Trials as Topic , Drug Administration Schedule , Female , Humans , Itraconazole , Ketoconazole/administration & dosage , Ketoconazole/therapeutic use , Male , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...